I'm not in NEU any more, haven't been for a while, but it's good to see 2591 getting some clinical validation in a Ph II trial.
There was always the possibility that it was going to be the better asset, long term, than 2256. While I can understand the company had very limited resources a few years ago, I was always annoyed that it wasn't pushed harder at the time.
I also felt the deal with Acadia made it harder for Neuren to develop 2591, and that was a key reason I quit being an investor.
But I'm not here to gripe, to me it looks like now Neuren has the money in the bank (and ongoing royalties) to push 2591 into Phase III and you'll all find out whether it is the broad-based neurodevelopmental drug that it could be.
Ann: Phase 2 trial shows significant improvements in Angelman, page-53
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |